Castle Biosciences
Castle Biosciences Gains New York State Approval for Pittsburgh Laboratory
The company can now serve NY state patients from either of its two facilities, in addition to populations across other US states under its existing CLIA certifications.
360Dx Top 30 Ticks Down in August
Out of the 30 companies in the index, 21 firms saw their stock prices decrease, while nine saw their share prices go up.
Castle Seeks to Dissipate Medicare Concerns as Q2 Revenues Rise 44 Percent
Despite recent reimbursement struggles, the company said it was raising its full-year guidance above its previously estimated $170 million to $180 million.
CMS Contractor Novitas Rescinds Noncoverage Decision for Cancer Genetic Tests
The original decision rescinded coverage for tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Abbott, Clinical Genomics, and the University of Pittsburgh Medical Center.
360Dx Top 30 Rebounds in June, Rising 4 Percent
Of the 30 companies in the Top 30, 20 saw their stock prices go up, while 10 saw their share prices decline.